INO-3107 Awarded The Innovation Passport Designation Under U.K. Government's Innovative Licensing And Access Pathway Granted By The ILAP Steering Group To INO-3107 For The Treatment Of Patients With Recurrent Respiratory Papillomatosis
Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP)PLYMOUTH MEETING, Pa., July 1
Redfin Reports Median U.S. Home Sale Price Hits All-Time High Of $397,482, Up 4.7% Year Over Year; Biggest Increase In Over Four Months; Price Growth May Slow As Homes Sell Below List Price, Inventory Rises, And Listings Grow Stale
Redfin Reports Median U.S. Home Sale Price Hits All-Time High Of $397,482, Up 4.7% Year Over Year; Biggest Increase In Over Four Months; Price Growth May Slow As Homes Sell Below List Price,
Envestnet Slips on Report of Bain, Reverence Nearing Takeover Deal
E2open Parent Holdings Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
E2open Parent Holdings Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
Ribbon Comms Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 50.6% Rosenblatt → $5 Initiates Coverage On → Buy 04/25/2024 95.78% B. Riley Securities $6 → $6
B&G Foods Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 4.03% Piper Sandler $9 → $8 Maintains Neutral 05/16/2024 17.04% Piper Sandler $9 → $9
Service Properties Trust Declares $0.20 Dividend
Seven Hills Realty Trust Declares $0.35 Dividend
Xponential Fitness Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 -17.45% Piper Sandler $9 → $14 Maintains Neutral 06/18/2024 17.92% Guggenheim $18 → $20
The Analyst Verdict: Itron In The Eyes Of 10 Experts
Throughout the last three months, 10 analysts have evaluated Itron (NASDAQ:ITRI), offering a diverse set of opinions from bullish to bearish.The table below provides a concise overview of recent
Unveiling 8 Analyst Insights On Alight
8 analysts have shared their evaluations of Alight (NYSE:ALIT) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings,
What Analysts Are Saying About Schrodinger Stock
During the last three months, 4 analysts shared their evaluations of Schrodinger (NASDAQ:SDGR), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent
Sally Beauty Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 30.78% Piper Sandler $14 → $13 Maintains Overweight 04/17/2024 10.66% TD Cowen $13 → $11
Inter Parfums Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 29.54% Piper Sandler $151 → $150 Maintains Overweight 05/09/2024 48.54% BWS Financial $172 → $1
Abercrombie & Fitch Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 — Argus Research Downgrades Buy → Hold 05/30/2024 10.47% Citigroup $150 → $190 Maintains
Hims & Hers Health Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 -11.11% Piper Sandler $16 → $18 Maintains Neutral 06/27/2024 13.58% Jefferies $14 → $23
Top 4 Real Estate Stocks That Could Lead To Your Biggest Gains In Q3
The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies. `The RSI is a momentum indicator, which compares a stock's strength on days when prices
Insiders Buying Fortress Biotech And 2 Other Stocks
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the
Vanda Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 105.61% Cantor Fitzgerald → $11 Initiates Coverage On → Overweight 02/25/2022 124.3%
Lantheus Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 19.7% Leerink Partners $106 → $127 Maintains Outperform 05/03/2024 -9.52% Truist Securities $82